Cure Alzheimer’s Fund Strengthens Leadership with New Board Appointments
TL;DR
Cure Alzheimer’s Fund strengthens its leadership with Christine Villas-Boas and Brittany Bowlen, enhancing strategic philanthropy to accelerate groundbreaking Alzheimer’s research.
Cure Alzheimer’s Fund appoints Christine Villas-Boas and Brittany Bowlen to its Board, leveraging their expertise in strategy and philanthropy to advance Alzheimer’s research funding.
Adding Christine Villas-Boas and Brittany Bowlen to Cure Alzheimer’s Fund’s Board amplifies efforts to combat Alzheimer’s, promising a brighter future for affected families worldwide.
Christine Villas-Boas and Brittany Bowlen join Cure Alzheimer’s Fund’s Board, bringing fresh energy and diverse experience to the fight against Alzheimer’s disease.
Found this article helpful?
Share it with your network and spread the knowledge!
The Cure Alzheimer’s Fund, a nonprofit organization at the forefront of funding research to combat Alzheimer’s disease, has announced the appointment of Christine Villas-Boas and Brittany Bowlen to its Board of Directors. This strategic move is set to inject fresh perspectives and expertise into the organization's efforts to find a cure for Alzheimer’s, a disease that affects millions worldwide.
Henry McCance, Board Chair and Co-Founder of Cure Alzheimer’s Fund, highlighted the significance of these appointments, noting the unique passion and perspective each new member brings to the table. Christine Villas-Boas, with her extensive background in finance and philanthropy, and Brittany Bowlen, known for her leadership in consulting and professional sports, are expected to play pivotal roles in advancing the fund's mission.
The addition of Villas-Boas and Bowlen to the board underscores the organization's commitment to leveraging diverse leadership and strategic insight to accelerate research efforts. Their appointments come at a critical time when the global community is in dire need of innovative solutions to tackle Alzheimer’s disease, which continues to pose significant challenges to healthcare systems and families around the world.
Since its inception in 2004, Cure Alzheimer’s Fund has been instrumental in funding over 300 leading researchers and contributing more than $232 million to research. The organization's dedication to transparency and efficiency, evidenced by its perfect score from Charity Navigator and Platinum Seal of Transparency from Candid, further solidifies its position as a key player in the fight against Alzheimer’s.
The implications of these new appointments extend beyond the organization, offering hope to millions affected by Alzheimer’s disease. By bolstering its leadership with individuals who bring a blend of professional excellence and personal commitment to the cause, Cure Alzheimer’s Fund is poised to make even greater strides in its mission to find a cure.
Curated from News Direct
